KLK3 and prostate carcinoma: Etoposide treatment dose-dependently inhibited AR-mediated cell growth, AR transcription, AR nuclei translocation, binding of androgen to AR, AR mRNA and protein expression level, and production of PSA in LNCaP prostate cancer cells [109].